Research ArticleMetabolism

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

See allHide authors and affiliations

Science Translational Medicine  03 Mar 2021:
Vol. 13, Issue 583, eabc8980
DOI: 10.1126/scitranslmed.abc8980

Article Information

vol. 13 no. 583

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication May 28, 2020
  • Accepted for publication February 5, 2021
  • .

Author Information

  1. Emily K. Sims1,
  2. Brian N. Bundy3,
  3. Kenneth Stier4,
  4. Elisavet Serti5,
  5. Noha Lim5,
  6. S. Alice Long6,
  7. Susan M. Geyer7,
  8. Antoinette Moran8,
  9. Carla J. Greenbaum6,
  10. Carmella Evans-Molina1,2,
  11. Kevan C. Herold4,*,
  12. Type 1 Diabetes TrialNet Study Group
  1. 1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  2. 2Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
  3. 3Department of Epidemiology, and Pediatrics University of South Florida, Tampa, FL 33612, USA.
  4. 4Departments of Immunobiology and Internal Medicine, Yale University, New Haven, CT 06520, USA.
  5. 5Immune Tolerance Network, Bethesda, MD 20814, USA.
  6. 6Benaroya Research Institute, Seattle WA 98101, USA.
  7. 7Mayo Clinic, Rochester, MN 55905, USA.
  8. 8Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.
  1. *Corresponding author. Email: kevan.herold{at}yale.edu
    • Type 1 Diabetes TrialNet Study Group investigators are listed in the Acknowledgments.

    Altmetric

    Article usage

    Article usage: March 2021 to June 2021

    AbstractFullPdf
    Mar 2021146378631433
    Apr 20211452203193
    May 20211441159119
    Jun 20218809181

    Stay Connected to Science Translational Medicine